347 related articles for article (PubMed ID: 19946220)
1. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.
Narizhneva NV; Tararova ND; Ryabokon P; Shyshynova I; Prokvolit A; Komarov PG; Purmal AA; Gudkov AV; Gurova KV
Cell Cycle; 2009 Dec; 8(24):4155-67. PubMed ID: 19946220
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
3. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
4. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
7. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
8. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
9. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
10. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
Kim Y; Kim J; Jang SW; Ko J
Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
12. ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.
Fleyshman D; Cheney P; Ströse A; Mudambi S; Safina A; Commane M; Purmal A; Morgan K; Wang NJ; Gray J; Spellman PT; Issaeva N; Gurova K
Cell Cycle; 2016; 15(3):455-70. PubMed ID: 26694952
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
15. ARF represses androgen receptor transactivation in prostate cancer.
Lu W; Xie Y; Ma Y; Matusik RJ; Chen Z
Mol Endocrinol; 2013 Apr; 27(4):635-48. PubMed ID: 23449888
[TBL] [Abstract][Full Text] [Related]
16. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
[TBL] [Abstract][Full Text] [Related]
18. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
20. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
